varenicline has been researched along with Diabetes Mellitus, Type 2 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alamo, A; Caci, G; Campagna, D; Caponnetto, P; Cibella, F; Di Mauro, M; Franek, E; Frittitta, L; Krysinski, A; Maglia, M; Polosa, R; Russo, C; Walicka, M | 1 |
| Alamo, A; Campagna, D; Caponnetto, P; Cibella, F; Di Mauro, M; Franek, E; Frittitta, L; Krysiński, A; Leotta, C; Maglia, M; Mondati, E; Polosa, R; Russo, C | 1 |
| Abughosh, SM; Chen, H; Essien, EJ; Johnson, ML; Peters, RJ; Wu, IH; Yang, M | 1 |
| Cedillo, S; Fernández de Bobadilla, J; Jiménez-Ruiz, CA; Rejas-Gutiérrez, J; Sicras-Mainar, A | 1 |
| Anthenelli, RM | 1 |
2 trial(s) available for varenicline and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Topics: Benzazepines; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline | 2022 |
A double blind randomized controlled trial investigating efficacy and safety of varenicline for smoking cessation in patients with type 2 diabetes: study protocol.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult | 2021 |
3 other study(ies) available for varenicline and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers.
Topics: Adolescent; Adult; Aged; Bupropion; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Uptake Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Nicotinic Agonists; Obesity; Proportional Hazards Models; Retrospective Studies; Risk; Smoking; Smoking Cessation; Varenicline; Young Adult | 2015 |
Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
Topics: Adult; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Pulmonary Disease, Chronic Obstructive; Smoking Cessation; Spain; Varenicline | 2017 |
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence.
Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |